Guidance

Hib/MenC: patient group direction (PGD) template

PGD template to support the national Haemophilus influenzae type b and meningococcal C conjugate vaccination programme.

• From: UK Health Security Agency
• Published: 4 February 2016
• Last updated: 26 June 2024 — See all updates

Applies to England

Documents

Hib/MenC: patient group direction (PGD) template

Ref: UKHSA gateway number GOV-12448

MS Word Document, 122 KB

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Notice of extension of the validity of Hib/MenC PGD

Ref: UKHSA gateway number GOV-12448

MS Word Document, 116 KB

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

This patient group direction (PGD) template supports the administration of Haemophilus influenzae type b (Hib) and meningococcal C conjugate vaccine to individuals from their first birthday to under 10 years of age in accordance with the national immunisation programme; and to individuals of any age for the prevention of secondary cases of meningococcal group C (MenC) disease in accordance with the Guidance for the public health management of meningococcal disease in the UK.

The Hib/MenC PGD version 05.00 is valid from 31 July 2022 to 1 August 2024 2024 and has been extended to 31 July 2025, when it is anticipated all centrally-held stocks of Menitorix® will be depleted. Further communication in respect of the changes to the childhood immunisation schedule will be received before this point.

Once locally held stocks are depleted and Menitorix® is no longer available from ImmForm, the authorising manager (as per section 7 of the PGD) should retire this PGD.

Practitioners must not use this PGD template until it has been authorised in Section 2. This is a legal requirement (see Human Medicines Regulations 2012). Practitioners should follow local policy/procedures to access authorised PGD documents.

This PGD template should be used with reference to current national guidance, the Green Book, and Summary of Product Characteristics for the vaccine.

Published 4 February 2016
Last updated 26 June 2024 + show all updates

1. 26 June 2024

   Added 'Notice of extension of the validity of Hib/MenC PGD'.

2. 30 June 2022

   Added version 5.

3. 2 July 2020

   Added V04.00: routine review.

4. 3 July 2018

   Updated template to align with new guidance for the public health management of Meningococcal disease in the UK.

5. 2 August 2016

   Updated to reflect removal of monovalent MenC from routine programme.

6. 4 February 2016

   First published.